Author: admin

Capture and Connect: Digital Business Cards Enhance Engagement at Events

In the dynamic landscape of modern events, meaningful connections are more valuable than ever. Popl, a leader in digital business card technology, highlights how their innovative solution is transforming event networking, making it more efficient, sustainable, and impactful.

The Evolution of Event Networking

Traditional business cards have long been a staple at events, but their limitations are becoming increasingly apparent in today’s fast-paced, tech-driven environment. 

Digital business cards offer a forward-thinking alternative that aligns with the needs of modern professionals, providing a seamless way to capture contact information and establish connections on the spot. You can add a link to your card to your email signature to share your details whenever you send an email, thus helping you expand your network. 

Enhancing Engagement and Connection

Digital business cards allow users to share their contact details with just a tap or scan, eliminating the need for physical cards and ensuring that every interaction is streamlined and memorable. 

This technology not only simplifies the process of exchanging information but also enhances the likelihood of follow-up, as contacts can be saved directly to smartphones and integrated with CRM systems.

Gerald Lombardo, a sales executive at Popl, explains, “At events, time is of the essence. Digital business cards make it easier to connect with others quickly and effectively, ensuring that no opportunity is missed.”

Sustainability Meets Innovation

In addition to improving efficiency, digital business cards offer a sustainable alternative to traditional paper cards. By reducing the reliance on physical materials, digital business card helps organizations minimize their environmental footprint while still maximizing their networking potential.

Lombardo adds, “Sustainability is a growing priority for many organizations. Digital business cards provide a way to engage with others responsibly, without compromising on impact or effectiveness.”

Data-Driven Networking

One of the key advantages of digital business cards is the ability to track engagement and gather insights. The best digital business card providers offers analytics that allow users to see who has viewed their card, when, and how often. This data-driven approach enables professionals to follow up more strategically and tailor their communication to the needs and interests of their contacts. 

You can go a step further and use the best email signature generator to create a professional email signature with a QR code and links to your LinkedIn and social media profiles to connect with other event attendees on a deeper level. 

Optimizing Event Experiences

By integrating digital business cards into their event strategy, organizations can create a more cohesive and engaging experience for attendees. This new technology supports not just individual networking but also enhances the overall flow of events, making it easier for participants to connect, share information, and build relationships that last.

About Popl

Popl is a pioneering company in the digital networking space, offering innovative solutions that empower professionals and organizations to connect seamlessly. Through its cutting-edge digital business cards, Popl is transforming the way people network at events and beyond.

Media Contact
Company Name: Popl.co
Contact Person: Gerald Lombardo
Email: Send Email
City: Los Angeles
State: CA
Country: United States
Website: https://popl.co

B-Cell Non-Hodgkin Lymphoma Pipeline Drugs 2024

DelveInsight’s, “B-Cell Non-Hodgkin Lymphoma Pipeline Insight 2024” report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in B-Cell Non-Hodgkin Lymphoma pipeline landscape. It covers the B-Cell Non-Hodgkin Lymphoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the B-Cell Non-Hodgkin Lymphoma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Explore our latest breakthroughs in B-Cell Non-Hodgkin Lymphoma Research. Learn more about our innovative pipeline today! @ B-Cell Non-Hodgkin Lymphoma Pipeline Outlook

 

Key Takeaways from the B-Cell Non-Hodgkin Lymphoma Pipeline Report

  • August 2024:- Hoffmann-La Roche- An Open-Label, Multi-Center, Phase IB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin (Plus a Single Pre-Treatment Dose of Obinutuzumab) in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma.
  • August 2024:- Bayer- A Phase III, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Copanlisib in Combination With Rituximab in Patients With Relapsed Indolent B-cell Non-Hodgkin’s Lymphoma (iNHL) – CHRONOS-3. The purpose of this study was to evaluate whether copanlisib in combination with rituximab is superior to placebo in combination with rituximab in prolonging progression free survival (PFS) in patients with relapsed iNHL who have received one or more lines of treatment, including rituximab and who either had a treatment-free interval of ≥ 12 months after completion of the last rituximab-containing treatment, or who are unwilling to receive chemotherapy/for whom chemotherapy is contraindicated on reason of age, comorbidities, and/or residual toxicity.
  • DelveInsight’s B-Cell Non-Hodgkin Lymphoma pipeline report depicts a robust space with 75+ active players working to develop 80+ pipeline therapies for B-Cell Non-Hodgkin Lymphoma treatment.
  • The leading B-Cell Non-Hodgkin Lymphoma Companies such as Xencor, MEI Pharma, Celldex Therapeutics, TG Therapeutics, Shanghai Unicar-Therapy Bio-medicine Technology, Chia Tai Tianqing Pharmaceutical Group, Mustang Bio, Novartis, Loxo Oncology, Genmab, Nkarta, Nurix Therapeutics, Prelude Therapeutics, and others.
  • Promising B-Cell Non-Hodgkin Lymphoma Therapies such as CD19 CAR-T cells, HY004, Glofitamab, Atezolizumab, Obinutuzumab, Copanlisib (Aliqopa, BAY80-6946), Rituximab, Odronextamab, DZD8586, IMPT-314, and others.

 

Stay informed about the cutting-edge advancements in B-Cell Non-Hodgkin Lymphoma Treatments. Download for updates and be a part of the revolution in care @ B-Cell Non-Hodgkin Lymphoma Clinical Trials Assessment

 

B-Cell Non-Hodgkin Lymphoma Emerging Drugs Profile

  • Valemetostat: Daiichi Sankyo

Valemetostat is an investigational and potential first-in-class EZH1/2 dual inhibitor in phase II clinical development for hematologic cancers including acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), and Non-Hodgkin lymphoma (NHL), including adult T-cell leukemia/lymphoma (ATL/L), peripheral T-cell lymphoma (PTCL), and B-cell lymphomas.

  • MB-106: Mustang Bio

MB-106 is a CD20-targeted autologous CAR T cell therapy developed for the treatment of B-cell non-Hodgkin lymphomas (B-NHLs) and chronic lymphocytic leukemia (CLL). This therapy, optimized as a third-generation CAR derived from a fully human antibody, has shown promising results in clinical trials. Currently, the drug is in Phase I/II stage of its clinical trial for the treatment of B-cell non-Hodgkin lymphoma.

  • CB-010: Caribou Biosciences

CB-010, our lead clinical-stage program, is an allogeneic anti-CD19 CAR-T cell therapy designed for patients with relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL). It is the first known allogeneic CAR-T cell therapy in clinical trials to incorporate a PD-1 knockout, utilizing a genome-editing strategy aimed at enhancing antitumor activity by preventing premature CAR-T cell exhaustion. The manufacturing process for CB-010 involves three key edits using Cas9 chRDNA guides: knocking out the TRAC gene to remove the T cell receptor, site-specific insertion of an anti-CD19 CAR into the TRAC gene, and knocking out PD-1. Currently, the drug is in Phase I stage of its clinical trial for the treatment of r/r B-NHL.

  • LP-284: Lantern Pharma

LP-284 is an innovative small molecule drug developed by Lantern Pharma, designed to selectively target cancer cells with mutations in DNA damage repair pathways. Its development is accelerated by AI and biological modeling through Lantern’s RADR platform. The FDA has granted orphan drug designation to LP-284 for treating high-grade B-cell lymphoma (HGBL) with MYC and BCL2 rearrangements. Currently, the drug is in Phase I stage of its clinical trial.

 

Learn more about B-Cell Non-Hodgkin Lymphoma Drugs opportunities in our groundbreaking B-Cell Non-Hodgkin Lymphoma Research and development projects @ B-Cell Non-Hodgkin Lymphoma Unmet Needs

 

B-Cell Non-Hodgkin Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

  • Oral
  • Intravenous
  • Subcutaneous
  • Parenteral
  • Topical

 

B-Cell Non-Hodgkin Lymphoma Products have been categorized under various Molecule types such as

  • Recombinant fusion proteins
  • Small molecule
  • Monoclonal antibody
  • Peptide
  • Polymer
  • Gene therapy

 

Discover the latest advancements in B-Cell Non-Hodgkin Lymphoma Treatment by visiting our website. Stay informed about how we’re transforming the future of Oncology @ B-Cell Non-Hodgkin Lymphoma Market Drivers and Barriers, and Future Perspectives

 

Scope of the B-Cell Non-Hodgkin Lymphoma Pipeline Report

  • Coverage- Global
  • B-Cell Non-Hodgkin Lymphoma Companies- Xencor, MEI Pharma, Celldex Therapeutics, TG Therapeutics, Shanghai Unicar-Therapy Bio-medicine Technology, Chia Tai Tianqing Pharmaceutical Group, Mustang Bio, Novartis, Loxo Oncology, Genmab, Nkarta, Nurix Therapeutics, Prelude Therapeutics, and others.
  • B-Cell Non-Hodgkin Lymphoma Therapies- CD19 CAR-T cells, HY004, Glofitamab, Atezolizumab, Obinutuzumab, Copanlisib (Aliqopa, BAY80-6946), Rituximab, Odronextamab, DZD8586, IMPT-314, and others.
  • B-Cell Non-Hodgkin Lymphoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • B-Cell Non-Hodgkin Lymphoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

 

For a detailed overview of our latest research findings and future plans, read the full details of B-Cell Non-Hodgkin Lymphoma Pipeline on our website @ B-Cell Non-Hodgkin Lymphoma Drugs and Companies

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. B-Cell Non-Hodgkin Lymphoma: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. B-Cell Non-Hodgkin Lymphoma– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Drug name: Company name
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. Valemetostat: Daiichi Sankyo
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. CB-010: Caribou Biosciences
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug name: Company name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. B-Cell Non-Hodgkin Lymphoma Key Companies
  21. B-Cell Non-Hodgkin Lymphoma Key Products
  22. B-Cell Non-Hodgkin Lymphoma- Unmet Needs
  23. B-Cell Non-Hodgkin Lymphoma- Market Drivers and Barriers
  24. B-Cell Non-Hodgkin Lymphoma- Future Perspectives and Conclusion
  25. B-Cell Non-Hodgkin Lymphoma Analyst Views
  26. B-Cell Non-Hodgkin Lymphoma Key Companies
  27. Appendix

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: yash bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: B-Cell Non-Hodgkin Lymphoma Pipeline Drugs 2024

Construction Sealants Market Size Analysis, Growth, Opportunities, Top Manufacturers, Share, Trends, Key Segmentation, Regional Analysis, and Forecast to 2028

“Browse 285 market data Tables and 41 Figures spread through 264 Pages and in-depth TOC on “Construction Sealants Market””
The construction sealants market is expanding due to rising building projects and renovation activities. Key drivers include demand for weatherproofing, energy efficiency, and enhanced durability. Innovations in sealant formulations and applications are fueling growth.

The global construction sealants market is projected to grow from USD 4.7 billion in 2023 and is projected to reach USD 5.7 billion by 2028, at a CAGR of 3.6%, between 2023 and 2028 period. There is high demand for construction sealants in the emerging markets of Asia Pacific due to the significant growth of the construction industry. Environment-friendly characteristics, durability, and better aesthetic appearance drive consumption in various applications.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=104100934 

Silicone sealants are the largest resin type in the market, primarily due to their excellent mechanical properties, such as elasticity, tensile strength, ultimate elongation, and tear resistance. Silicone sealants are the most versatile, with a wide range of properties, including low thermal conductivity, low chemical reactivity, low toxicity, and thermal stability. The significant ones include weather, heat and microbial resistance, water and vapor permeability, and resistance to extreme temperatures.

Asia Pacific is the fastest-growing and largest construction sealants industry. Development in both the residential and non-residential sectors is likely to drive the demand for construction sealants in this region, especially in China and India, during the forecast period. China is the main driving force behind the fast expansion of the construction sealants market not only in the Asia Pacific region but also across the globe. Factors such as rapidly growing construction activities and a huge and increasing addressable population base are driving the construction sealants market in the Asia Pacific region.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=104100934 

Glazing accounts for the largest market share of the construction sealants market in the application segment between 2023 and 2028. The rising demand for sealants from the glazing application can be attributed to the increasing requirement for residential housing, theme parks, hotels, and other commercial centers in developed nations for new work, renovation, maintenance, and repairs.

Continuous developments in the construction sealants market are expected to help the market grow. The companies are providing products that will serve various applications. Acquisitions have also helped companies to have a greater reach. The companies have also started new manufacturing sites to capture and fulfill the need of the market.

The key players following the strategies between 2018 and 2023 are 3M (US), Arkema (France), Sika AG (Switzerland), Henkel AG & Co. KGaA (Germany), and H.B. Fuller (US). The companies are majorly following acquisition as the strategy to grow and expand the market.

Request Customization: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=104100934 

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America’s best management consulting firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

Earlier this year, we made a formal transformation into one of America’s best management consulting firms as per a survey conducted by Forbes.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the ‘GIVE Growth’ principle, we work with several Forbes Global 2000 B2B companies – helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:630 Dundee Road Suite 430
City: Northbrook
State: IL 60062
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/construction-sealants-market-104100934.html

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Construction Sealants Market Size Analysis, Growth, Opportunities, Top Manufacturers, Share, Trends, Key Segmentation, Regional Analysis, and Forecast to 2028

Secrets to Long, Beautiful Lashes: The Ultimate Guide to Choosing the Right Lash Growth Serum

Dreaming of long, luscious lashes? With so many lash growth serums on the market, picking the right one can be overwhelming. Here’s your guide to finding the perfect lash serum for stunning results:

1. Understand the Ingredients

  • Prostaglandin Analogues: Potent and effective, these ingredients can dramatically enhance lash length and thickness. Products with prostaglandin analogues often deliver noticeable results but may cause side effects like irritation or darkening of the eyelid.
  • Peptides: Peptides strengthen and nourish lashes, promoting healthier growth. They’re gentler than prostaglandins, making them ideal for sensitive eyes.
  • Biotin & Panthenol: These vitamins nourish and condition lashes, making them stronger and less prone to breakage. Look for serums with these ingredients if you want to maintain healthy lashes.
  • Botanical Extracts: Serums with natural plant extracts are a great option if you prefer a more natural approach. They tend to be gentler on the skin and lashes.

2. Check for Clinical Testing

  • Choose serums that have been dermatologically and ophthalmologically tested. This ensures they are safe for use around the delicate eye area and are less likely to cause irritation.

3. Consider Your Eye Sensitivity

  • If you have sensitive eyes or wear contact lenses, opt for a serum formulated for sensitive skin. These are usually free of harsh chemicals and fragrances.

4. Consistency is Key

  • Whichever serum you choose, consistency is vital. Most serums require daily application for at least 8–12 weeks before you see significant results.

5. Read Reviews and Do Your Research

  • Before making a purchase, read user reviews and testimonials. Look for before-and-after photos to gauge the effectiveness of the product.

6. Budget Wisely

  • Lash serums can range from budget-friendly to luxury prices. While expensive doesn’t always mean better, it’s often worth investing in a reputable product for the best results.

7. Watch for Red Flags

  • Avoid products with unclear ingredient lists or exaggerated claims. If something sounds too good to be true, it probably is.

With the right lash serum, you can achieve the fuller, longer lashes you’ve always wanted. Just remember to be patient and consistent in your application. Happy lash growing!

Media Contact
Company Name: QueenLash
Contact Person: Leo Jade
Email: Send Email
Phone: +33 96 936 2006
Address:87 Avenue Millies Lacroix
City: Dzaoudzi
State: Mayotte 97610
Country: France
Website: https://queenlashuk.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Secrets to Long, Beautiful Lashes: The Ultimate Guide to Choosing the Right Lash Growth Serum

Gastric Cancer Pipeline Drugs 2024 | Linton Pharm Co. Ltd., Shanghai Henlius Biotech, RAPT Therapeutics, AstraZeneca, Astellas Pharma, Minneamrita Therapeutics, Aston Science, Servier Bio-Innovation

DelveInsight’s, “Gastric Cancer Pipeline Insight 2024” report provides comprehensive insights about 180+ companies and 200+ pipeline drugs in Gastric Cancer pipeline landscape. It covers the pipeline drug profiles, including Gastric Cancer clinical trials and nonclinical stage products. It also covers the Gastric Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Gastric Cancer Pipeline Report

  • August 2024:- Bold Therapeutics, Inc.- BOLD-100 is an intravenously administered sterile solution containing the ruthenium-based small molecule. BOLD-100 has been shown to preferentially decrease the expression of GRP78 in tumour cells and ER stressed cells when compared to normal cells. BOLD-100 will be combined with cytotoxic FOLFOX chemotherapy in this study, with a dose escalation cohort to ensure tolerability and safety, followed by a cohort expansion phase.
  • August 2024:- AstraZeneca- A Phase 1b/2 Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of Trastuzumab Deruxtecan (T-DXd) Monotherapy and Combinations in Adult Participants With HER2-expressing Gastric Cancer (DESTINY-Gastric-03)
  • DelveInsight’s Gastric Cancer pipeline report depicts a robust space with 180+ active players working to develop 200+ pipeline therapies for Gastric Cancer treatment.
  • The leading Gastric Cancer Companies such as Linton Pharm Co. Ltd., Shanghai Henlius Biotech, RAPT Therapeutics, AstraZeneca, Astellas Pharma, Minneamrita Therapeutics, Aston Science, Servier Bio-Innovation LLC, Bukwang Pharmaceutical, Taiho Oncology, Inc., Novartis Pharmaceuticals, Base Therapeutics (Shanghai) Co., Ltd, Shanghai Miracogen Inc., RemeGen Co., Ltd., Idience Co., Ltd., BeiGene, Ono Pharmaceutical Co. Ltd, Elevar Therapeutics, R-Pharm, Innovent Biologics (Suzhou) Co. Ltd., MacroGenics, Sichuan Baili Pharmaceutical Co., Ltd., LianBio LLC, and Janssen Pharmaceutical, and others.
  • Promising Gastric Cancer Therapies such as Avelumab, BBI608, Camrelizumab, Catumaxomab, RAPA-201, SHR-1210, Amivantamab, Atezolizumab, Bevacizumab, Cabozantinib, Cinrebafusp alfa, Crizotinib, DKN-01, DP303c, Eflornithine, EP0057, Epacadostat, FLX475, Futibatinib, GEN-001, HLX07, HLX22, Infigratinib, KH903, Lenvatinib, Masitinib, MAX-40279, MRG002, MRG003, Niraparib, Savolitinib, Minnelide, SHR-1701, Margetuximab, Bemarituzumab, Evorpacept, Lenvatinib, CDK-004, TPX-0022,  TCRx_T Cells,  IN10018, IMU-131, SOT102, CT041, AB011, Zanidatamab, NC410,  PT 886, PRS-343, Oraxol, CA-4948,  Q702,  ACE1702, SI-B001, TT-4, LUM015,  LB 1908, CUE-102,  TORL-2-307-MAB,  OBI-833/OBI-821,  ASP2138, NC410, SO-C101, HC-5404-FU, CPL304110,  LNS8801, RGX-202-01, A166, GZ17-6.02, HMPL-453,  CCT303-406, VMD-928,  ITI 4000, PAb 001, and others.

 

Explore our comprehensive Gastric Cancer Pipeline Report to stay informed about the latest advancements. Download copy now @ Gastric Cancer Pipeline Outlook

 

Gastric Cancer Overview

Gastric cancer, also known as stomach cancer, is a formidable adversary in the realm of oncology, characterized by the malignant growth of cells lining the stomach. This disease poses a significant global health burden, with varying incidence rates across different regions and populations. Gastric cancer often manifests silently, with symptoms appearing in advanced stages, making early detection and intervention crucial for successful treatment outcomes. Risk factors such as Helicobacter pylori infection, tobacco use, certain dietary habits, and genetic predisposition play pivotal roles in its development.

 

Gastric Cancer Emerging Drugs Profile

  • Catumaxomab: Linton Pharm Co. Ltd.

Catumaxomab is a bispecific monoclonal antibody that binds to EpCAM (the epithelial cell adhesion molecule) on the tumor cell–and CD3 on the T cell, recruits immune accessory cells through FcγR binding at the same time. Catumaxomab kills tumor cells by engaging T cell and accessory cell mediated cytotoxicity and has the potential to induce long-term vaccinal effects. It is co-developed by Trion Pharma and Neovii Biotech. Currently it is in Phase III stage of clinical trial evaluation to treat Gastric Cancer.

  • HLX10: Shanghai Henlius Biotech

HLX10, a novel recombinant humanized anti-programmed cell death protein 1 (PD-1) mAb independently developed by Henlius. The drug candidate works on programmed cell death-1 receptor antagonists and T lymphocyte stimulant mechanism of action. Currently being evaluated in the Phase III studies.

  • FLX475: RAPT Therapeutics

FLX475 is an oral, small molecule CCR4 antagonist designed to block the migration of regulatory T cells (Treg) specifically into tumors, but not healthy tissues, without depleting Treg throughout the body. It is in collaboration agreement with Hanmi for specific regions like Korea, Taiwan and China. Currently the drug is being evaluated in Phase II for the treatment of Gastric Cancer.

  • Savolitinib: AstraZeneca/HUTCHMED

Savolitinib is an oral, potent and highly selective MET tryokinase inhibitors (TKI). It blocks atypical activation of the MET receptor tyrosine kinase pathway that occurs because of mutations (such as exon 14 skipping alterations or other point mutations), gene amplification or protein overexpression. The drug is been developed under global licensing and collaboration agreement with AstraZeneca. The drug is in Phase II stage of clinical trials.

  • ASP 2138: Astellas Pharma

ASP-2138 is a bispecific antibody targeting CD3 and claudin 18.2 (CLDN18.2). It is administered through intravenous drip route. The drug candidate is being developed based on XmAb technology. The drug is under clinical development by Xencor and currently drug is in Phase I stage of clinical trials for the treatment of gastric cancer.

  • Minnelide : Minneamrita Therapeutics LLC

Minnelide is under clinical development by Minneamrita Therapeutics. It is administered through intravenous and oral routes. The drug candidate is a water soluble analogue of triptolide and is derived from the thunder God vine (Tripterygium wilfordii). It acts by targeting heat shock protein70 (Hsp70). Currently being investigated in a Phase I clinical trial in patients suffering with gastric cancer.

 

Dive into our Gastric Cancer Pipeline Report to uncover promising therapies and breakthroughs. Gain insights that could shape the future of oncology @ Gastric Cancer Treatment Therapies

 

Gastric Cancer Therapeutics Assessment

There are approx. 180+ key companies which are developing the therapies for Gastric Cancer. The Gastric Cancer companies which have their Gastric Cancer drug candidates in the most advanced stage, i.e. phase III include, Linton Pharm Co. Ltd.

 

DelveInsight’s Gastric Cancer pipeline report covers around 200+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

 

Download the Gastric Cancer Pipeline Report to discover partnership opportunities and collaborate in driving impactful solutions forward @ Gastric Cancer Clinical Trials Assessment

 

Gastric Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical.

 

Gastric Cancer Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy

 

Dive into our detailed Gastric Cancer Pipeline Report to discover groundbreaking advancements shaping the future of cancer treatment @ Gastric Cancer Products, Companies, and Unmet Needs

 

Scope of the Gastric Cancer Pipeline Report

  • Coverage- Global
  • Gastric Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Gastric Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Gastric Cancer Companies- Linton Pharm Co. Ltd., Shanghai Henlius Biotech, RAPT Therapeutics, AstraZeneca, Astellas Pharma, Minneamrita Therapeutics, Aston Science, Servier Bio-Innovation LLC, Bukwang Pharmaceutical, Taiho Oncology, Inc., Novartis Pharmaceuticals, Base Therapeutics (Shanghai) Co., Ltd, Shanghai Miracogen Inc., RemeGen Co., Ltd., Idience Co., Ltd., BeiGene, Ono Pharmaceutical Co. Ltd, Elevar Therapeutics, R-Pharm, Innovent Biologics (Suzhou) Co. Ltd., MacroGenics, Sichuan Baili Pharmaceutical Co., Ltd., LianBio LLC, and Janssen Pharmaceutical, and others.
  • Gastric Cancer Therapies- Avelumab, BBI608, Camrelizumab, Catumaxomab, RAPA-201, SHR-1210, Amivantamab, Atezolizumab, Bevacizumab, Cabozantinib, Cinrebafusp alfa, Crizotinib, DKN-01, DP303c, Eflornithine, EP0057, Epacadostat, FLX475, Futibatinib, GEN-001, HLX07, HLX22, Infigratinib, KH903, Lenvatinib, Masitinib, MAX-40279, MRG002, MRG003, Niraparib, Savolitinib, Minnelide, SHR-1701, Margetuximab, Bemarituzumab, Evorpacept, Lenvatinib, CDK-004, TPX-0022,  TCRx_T Cells,  IN10018, IMU-131, SOT102, CT041, AB011, Zanidatamab, NC410,  PT 886, PRS-343, Oraxol, CA-4948,  Q702,  ACE1702, SI-B001, TT-4, LUM015,  LB 1908, CUE-102,  TORL-2-307-MAB,  OBI-833/OBI-821,  ASP2138, NC410, SO-C101, HC-5404-FU, CPL304110,  LNS8801, RGX-202-01, A166, GZ17-6.02, HMPL-453,  CCT303-406, VMD-928,  ITI 4000, PAb 001, and others.

 

Gain valuable insights into emerging therapies and innovations with our Gastric Cancer Pipeline Report @ Gastric Cancer Market Drivers and Barriers, Future Perspectives and Analyst Views

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Gastric Cancer: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Late Stage Products (Phase III)
  7. Comparative Analysis
  8. Catumaxomab : Neovii Biotech
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. FLX475: RAPT Therapeutics
  12. Early Stage Products (Phase I)
  13. Comparative Analysis
  14. ASP 2138: Astellas Pharma
  15. Inactive Products
  16. Gastric Cancer Key Companies
  17. Gastric Cancer Key Products
  18. Gastric Cancer – Unmet Needs
  19. Gastric Cancer – Market Drivers and Barriers
  20. Gastric Cancer – Future Perspectives and Conclusion
  21. Gastric Cancer Analyst Views
  22. Gastric Cancer Key Companies
  23. Appendix

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Gastric Cancer Pipeline Drugs 2024 | Linton Pharm Co. Ltd., Shanghai Henlius Biotech, RAPT Therapeutics, AstraZeneca, Astellas Pharma, Minneamrita Therapeutics, Aston Science, Servier Bio-Innovation

Floor Adhesive Market Growth, Global Size, Opportunities, Leading Manufacturers, Key Segmentation, Regional Analysis, and Forecast to 2028

“Browse 160 market data Tables and 60 Figures spread through 260 Pages and in-depth TOC on “Floor Adhesive Market””
The floor adhesive market is growing due to increased construction and renovation activities. Demand is driven by innovations in adhesive formulations for various flooring types, including vinyl, laminate, and carpet, and a focus on durability and ease of application.

The global floor adhesives market size is projected to grow from USD 9.7 billion in 2023 to USD 12.8 billion, at a CAGR of 5.8%. Within the dynamic realm of the floor adhesives market, two distinct factors emerge as pivotal drivers, orchestrating its trajectory and shaping its growth dynamics. These factors, each possessing unique significance, jointly contribute to the industry’s evolution and expansion, warranting strategic attention from industry stakeholders and decision-makers.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=37475603  

The proliferation of urbanization and construction activities on a global scale stands as a formidable driver propelling the floor adhesives market. Rapid urbanization, particularly in emerging economies, has precipitated a surge in construction projects spanning residential, commercial, and industrial domains. As these structures take shape, the demand for dependable and versatile flooring solutions gains prominence, underscoring the indispensability of robust and high-performing floor adhesives. Moreover, the growing need for infrastructure development and modernization amplifies the market’s significance, as adhesives serve as linchpins in ensuring enduring and aesthetically pleasing flooring installations, thereby carving a path of sustained growth for the industry.

The unwavering emphasis on sustainability and eco-conscious construction practices exerts a profound influence, propelling the floor adhesives industry in an environmentally responsible direction. Regulatory mandates, coupled with heightened consumer awareness of environmental impact, underscore the need for adhesives that align with low Volatile Organic Compounds (VOC) standards and eco-friendly formulations. This demand for sustainable adhesives creates an impetus for manufacturers to innovate, offering products that not only adhere to stringent regulations but also resonate with the evolving preferences of environmentally-conscious consumers. Consequently, the drive towards sustainable construction bolsters the market’s expansion by fostering a distinct niche for eco-friendly floor adhesives

The Asia Pacific region has asserted itself as the largest consumer within the floor adhesives market, a distinction underpinned by a confluence of strategic factors that align favorably with the industry’s offerings and growth dynamics. This prominence within the market landscape is emblematic of the region’s burgeoning construction activities, evolving consumer preferences, and the symbiotic relationship between economic expansion and adhesive demand. Foremost among the factors driving Asia Pacific’s preeminence is the region’s unparalleled urbanization and rapid infrastructural development. As emerging economies within Asia Pacific experience exponential population growth and urban migration, the demand for residential, commercial, and industrial infrastructure escalates significantly. This translates into an augmented requirement for reliable and durable flooring solutions, wherein floor adhesives play a pivotal role in ensuring flooring installations’ longevity and aesthetic appeal. The sheer scale of construction projects across the region’s diverse geographies underscores the essentiality of floor adhesives, thereby propelling substantial demand.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=37475603 

The preference for epoxy resin type within the floor adhesives market is underpinned by a strategic amalgamation of attributes that make it a compelling and advantageous choice for a diverse range of flooring applications. This predilection underscores a pursuit of high performance, durability, versatility, and operational efficiency, rendering epoxy resin adhesives a preferred and trusted option within the industry. A primary driver behind the widespread adoption of epoxy resin type lies in its exceptional bonding strength and durability. Epoxy adhesives exhibit robust adhesion to a multitude of substrates, including concrete, ceramics, and wood. This steadfast bond not only ensures the longevity of flooring installations but also contributes to their structural integrity, making epoxy resin adhesives an indispensable choice for high-traffic and heavy-load areas. The ability to withstand mechanical stresses, foot traffic, and environmental conditions bolsters the reliability of epoxy-based flooring installations, thereby accentuating its prominence.

The preference for water-based technology within the floor adhesives market is grounded in a strategic convergence of factors that accentuate its inherent advantages and align with contemporary industry imperatives. This choice underscores the pursuit of operational efficiency, environmental responsibility, and performance excellence, making water-based technology a compelling and preferred option for adhesive formulations. A key driver behind the widespread adoption of water-based technology lies in its inherent eco-friendliness and alignment with sustainability objectives. As regulatory mandates and consumer awareness propel industries towards greener practices, water-based adhesives emerge as a conscientious choice. These formulations typically exhibit lower levels of Volatile Organic Compounds (VOCs), which are detrimental to indoor air quality and the environment. The reduction in VOC emissions not only complies with stringent environmental regulations but also resonates positively with environmentally-conscious consumers and project stakeholders. This alignment with sustainability goals fortifies the appeal of water-based adhesives and positions them as a responsible choice in the market.

Inquire Now: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=37475603 

There are various small, medium, and large players operating in the market. Some of the major market players include Henkel AG (Germany), H.B. Fuller (US), Sika AG (Switzerland), Arkema (Bostik SA) (France), 3M (US), Dow Inc (US), Wacker Chemie AG (Germany), and Pidilite Industries Limited (India) among others, have framed their strategies to penetrate and create bases in these emerging markets. Furthermore, huge firms are attempting to improve their research and development facilities in order to provide more efficient and sustainable goods. These goods are made in compliance with the constraints set by organizations and governments. Over the next five years, all of these factors are expected to contribute to the long-term development of floor adhesives market participants.

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America’s best management consulting firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

Earlier this year, we made a formal transformation into one of America’s best management consulting firms as per a survey conducted by Forbes.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the ‘GIVE Growth’ principle, we work with several Forbes Global 2000 B2B companies – helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:630 Dundee Road Suite 430
City: Northbrook
State: IL 60062
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/floor-adhesive-market-37475603.html

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Floor Adhesive Market Growth, Global Size, Opportunities, Leading Manufacturers, Key Segmentation, Regional Analysis, and Forecast to 2028

SmartSuite Named Global SaaS Product of the Year at 2024 StartUp Grind Global Conference

“SmartSuite Named Global SaaS Product of the Year at 2024 StartUp Grind Global Conference”

REDWOOD CITY, CA – August 20, 2024 – SmartSuite, the work management platform that manages any process from any industry on one platform, is honored to be named the Global SaaS Product of the Year at the 2024 StartUp Grind Global Conference. The award, which was announced at the conference this past May in Redwood City, California, highlights SmartSuite’s innovative solutions in a competitive field of over 600 startups worldwide.

About StartUp Grind

StartUp Grind, a leading organization in the startup ecosystem, boasts a community of over 3.5 million entrepreneurs. The company’s annual Global Conference, featuring top SaaS leaders and notable speakers, is a premier event for showcasing industry advancements. This year’s conference included influential figures like Tim Draper and Romain Huet, placing SmartSuite among the leading innovators of the past five years.

About SmartSuite

In 2021, Jon Darbyshire and his team launched SmartSuite, a versatile work management platform designed to streamline processes across any industry and company size. This innovation builds on Jon’s extensive background in technology, including his founding of Archer Technologies in 2000, which revolutionized governance, risk, and compliance software and was acquired by EMC Corporation in 2010. Before Archer, Jon held leadership roles at EY and Price Waterhouse, focusing on automating business tasks to enhance efficiency. SmartSuite, developed by a dedicated team over three years, achieved $1M ARR in its first year. It is on track to triple its revenue in 2024, continuing Jon’s legacy of creating impactful, user-centric solutions.

SmartSuite’s Innovation

SmartSuite stands out with its AI-enabled work management platform, automating and streamlining business processes across diverse industries. Available in 15 languages and trusted by over 5,000 customers in more than 100 countries, SmartSuite simplifies operations and enhances team collaboration.

The rise of point solutions, often built on no-code and other platforms, has led to fragmented workflows and data silos. SmartSuite addresses these challenges with a unified platform offering capabilities in business process automation, project management, and more, effectively managing complex business needs.

Derek Andersen, CEO of StartUp Grind, praised SmartSuite’s achievement: “SmartSuite’s platform excels in unifying work management processes, setting a high standard in the SaaS space.”

“The SmartSuite team has built a work management platform that can be used to automate business processes for any company, from startups to enterprise,” says SmartSuite CEO Jon Darbyshire. “We have brought best in class software capabilities into the hands of everyone who needs it to run their business.”

SmartSuite is committed to further innovation and global expansion. Start a free trial today to explore how SmartSuite can transform your business.

For more information about the conference and our award, visit StartUp Grind Conference Details and Conference Speakers. For additional updates, check out our LinkedIn Post.

Media Contact:

Court Walker

Otter Public Relations

+1 (407) 453-2324

court.walker@otterpr.com

Media Contact
Company Name: SmartSuite
Contact Person: Court Walker
Email: Send Email
Country: United States
Website: https://www.smartsuite.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: SmartSuite Named Global SaaS Product of the Year at 2024 StartUp Grind Global Conference

Private Helicopter Tour Las Vegas | New Partnership Between Las Vegas Private Helicopter Tour Service & Papillon Private Helicopters Elevates Luxury Tourism

The Las Vegas helicopter tour scene just got even more exciting with the announcement of a new partnership between Las Vegas Private Helicopter Tour Service and the renowned Papillon Private Helicopters. This collaboration brings together two leaders in luxury aerial experiences, offering guests a truly unmatched opportunity to explore the breathtaking sights of Las Vegas, the Grand Canyon, and beyond. But it’s not just the stunning views that make this partnership so special — guests are in for a series of exceptional perks, including free dinners, vacation vouchers, and a 10% discount on all ride services.

The vision behind this partnership is to combine the bespoke, high-touch service offered by Las Vegas Private Helicopter Tour Service with Papillon’s vast experience and operational excellence. Together, they aim to create a seamless and lavish experience from start to finish, giving guests access to exclusive packages that include everything from luxury transportation to memorable dining experiences.

One of the highlights of this collaboration is the addition of free dinner vouchers for all guests. When you book a tour, you’re not only signing up for an incredible flight over the neon-lit Las Vegas Strip or the majestic Grand Canyon, but you’re also treated to a gourmet dinner at one of Las Vegas’s top restaurants. Whether you’re in the mood for a perfectly grilled steak, a fresh seafood dish, or a sophisticated vegetarian option, this dinner is the perfect way to unwind and reflect on your adventure.

In addition to the dining experience, guests receive complimentary vacation vouchers that can be redeemed for stays at luxurious Las Vegas resorts. These packages are designed to extend the sense of indulgence that the helicopter tour offers, giving you a few extra days to soak in the city’s luxury, entertainment, and fine dining. Imagine flying over the Grand Canyon during the day and retreating to a plush suite in a five-star hotel in the evening — this partnership makes that dream a reality.

The partnership also includes a 10% discount on all ride services, making transportation hassle-free from the moment you step off your flight. Whether you need a stylish ride from your hotel to the heliport, a limo service for a night out, or simply a comfortable transfer back to your accommodations, the discount ensures your experience remains smooth and luxurious.

The team at Las Vegas Private Helicopter Tour Service has always been dedicated to curating unforgettable experiences for their guests, and this new partnership with Papillon Private Helicopters takes that mission to a whole new level. By offering these incredible perks — free dinners, vacation vouchers, and discounted ride services — they’re not just selling helicopter tours; they’re creating a full-circle VIP experience that captures the best of what Las Vegas has to offer.

As word of these exclusive offerings spreads, demand is soaring, and this partnership is quickly becoming the go-to option for travelers who want more than just a tour — they want the full luxury treatment. From high above the shimmering lights of Las Vegas to the awe-inspiring depths of the Grand Canyon, this collaboration ensures that every aspect of your journey is nothing short of spectacular. Whether you’re celebrating a special occasion or simply indulging in the finer things in life, the Las Vegas Private Helicopter Tour Service and Papillon Private Helicopters partnership is the ultimate way to experience Sin City from a whole new perspective.

https://www.papillon.com/las-vegas-tours/helicopter-tours-from-las-vegas/private-tours

https://lasvegasprivatehelicoptertours.weebly.com/

https://www.eventective.com/myeventective/#/crm

https://maps.app.goo.gl/kcsPi3H7E9PHWK919

https://www.bing.com/maps?osid=64b27a8a-7d99-48ac-8f78-d9116cb9338c&cp=36.257176~-115.467141&lvl=11.25&pi=0&v=2&sV=2&form=S00027

Media Contact
Company Name: Las Vegas Private Helicopter Tour Service
Contact Person: Dujaun Hayles
Email: Send Email
Phone: 404-666-6031
Country: United States
Website: https://lasvegasprivatehelicoptertours.weebly.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Private Helicopter Tour Las Vegas | New Partnership Between Las Vegas Private Helicopter Tour Service & Papillon Private Helicopters Elevates Luxury Tourism

Glioblastoma Pipeline Drugs 2024 | Denovo BioPharma, Pfizer, Vigeo Therapeutics, Celldex Therapeutics, Debiopharm, Prelude Therapeutics, AiVita Biomedical, Ascletis Pharma

DelveInsight’s, “Glioblastoma Pipeline Insight 2024” report provides comprehensive insights about 195+ companies and 210+ pipeline drugs in Glioblastoma pipeline landscape. It covers the Glioblastoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Glioblastoma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Glioblastoma Pipeline Report

  • August 2024:- Acerta Pharma BV- A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM). A Phase 1b/2, multicenter, open-label study was designed to evaluate the efficacy and safety of acalabrutinib in subjects with recurrent glioblastoma multiforme (GBM) who had progressed after one or two prior systemic treatment regimens.
  • August 2024:- ImmunityBio Inc.- Open-label Phase 2 Study of N-803 and PD-L1 t-haNK Combined With Bevacizumab in Subjects With Recurrent or Progressive Glioblastoma. This is a phase 2 open-label study to evaluate the safety and efficacy of N-803 and PD-L1 t-haNK when combined with Bevacizumab in subjects with recurrent or progressive GBM.
  • DelveInsight’s Glioblastoma pipeline report depicts a robust space with 195+ active players working to develop 210+ pipeline therapies for Glioblastoma treatment.
  • The leading Glioblastoma Companies such as Denovo BioPharma, Pfizer, Vigeo Therapeutics, Celldex Therapeutics, Debiopharm, Prelude Therapeutics, AiVita Biomedical, Ascletis Pharma, Kintara Therapeutics, Bayer AG, Kazia Therapeutics, GlaxoSmithKline, Candel Therapeutics, Symphogen A/S, Sanofi, Oblato, Jiangsu Hengrui Medicine, BPGbio, Inc., Alaunos Therapeutics, Eli Lilly and Company, Actuate Therapeutics, Oncotelic Therapeutics, The Menarini Group, SonALAsense, Novartis, Allarity Therapeutics, PharmAbcine, I-Mab Biopharma Co. Ltd., Aadi Bioscience, Inc., Matrix Biomed, Photonamic GmbH & Co. KG, Lixte, Black Diamond Therapeutics, Tmunity Therapeutics, SOM Biotech, Moleculin, Xynomic Pharmaceuticals, OncoSynergy, and others.
  • Promising Glioblastoma Therapies such as Axumin, Intravenous Solution, PolyMVA, MDNA55, Erlotinib HCl (OSI-774), BPM31510, Temozolomide (TMZ), and others.

  

Explore our comprehensive Glioblastoma Pipeline Report to stay informed about the latest advancements. Download copy now @ Glioblastoma Pipeline Outlook

 

Glioblastoma Overview

Glioblastoma, often referred to as glioblastoma multiforme (GBM), is an aggressive and malignant form of brain tumor that originates in the glial cells of the brain. It is categorized as a grade IV astrocytoma, characterized by its rapid growth and invasive nature within the brain tissue. Glioblastomas are notorious for their resistance to treatment and high recurrence rates despite aggressive therapies such as surgery, radiation, and chemotherapy. Symptoms vary depending on the tumor’s location but commonly include headaches, nausea, cognitive impairment, and neurological deficits. The prognosis for glioblastoma remains challenging, with most patients facing a median survival of approximately 12 to 15 months after diagnosis, highlighting the urgent need for continued research into more effective treatments and therapies.

 

Glioblastoma Emerging Drugs Profile

  • Enzastaurin: Denovo BioPharma

DB102 (enzastaurin) is an orally available investigational first-in-class small molecule, serine/threonine kinase inhibitor of the PKC beta, PI3K, and AKT pathways that has been studied in more than 3,000 patients across a range of solid and hematological tumor types. DB102 was originally developed by Eli Lilly and for which Denovo has acquired worldwide rights. DB102 received Orphan Drug Designation in DLBCL and glioblastoma multiforme (GBM) from the FDA and EMA and Fast Track Designation from the FDA. DB102 is the world’s first oral small-molecule kinase inhibitor targeting PKC. A retrospective analysis found that it has significant curative effects in high-risk DLBCL patients who are DGM1 positive. The company has initiated a biomarker guided Phase III clinical study evaluating the DB102 (enzastaurin) in combination with temozolomide and radiation as first line therapy to treat newly-diagnosed glioblastoma multiforme (GBM).

  • Tofacitinib: Pfizer

Tofacitinib (Xeljanz, Jaquinus) is an immunosuppressant. It is a first-generation, orally bioavailable pan-Jak inhibitor. Tofacitinib was mainly developed for use as an immunosuppressant for organ transplantation and possibly for the treatment of autoimmune diseases. Tofacitinib suppresses the Jak family members at IC50s as follows: Jak1, Jak2, and Jak3, in a cell-free kinase assay. In addition, Tofacitinib effectively suppresses common γ-chain cytokines involving IL-2, IL-4, IL-15 and IL-21. Furthermore, the most common side effects include headaches, upper respiratory infections, diarrhea, and nasopharyngeal inflammation, elevation in low-density lipoprotein and cholesterol levels and reduction in neutrophil numbers. Serious infections including pneumonia, cellulitis and urinary tract infections have been described in patients treated with Tofacitinib. Currently, the drug is in the Phase III stage of its development for the treatment of glioblastoma multiforme.

  • VT1021: Vigeo Therapeutics

Vigeo’s lead asset, VT1021, is a first-in-class dual modulating compound that blocks the CD47 immune checkpoint and activates CD36, which induces apoptosis and increases the M1:M2 macrophage ratio. VT1021 achieves this through stimulation of thrombospondin-1 (Tsp-1). The goal of these dual-modulating effects is conversion of immuno-suppressive, or “cold,” tumors that don’t respond to immuno-oncology agents, to immuno-stimulated, or “hot,” tumors that are potentially more receptive to immuno-oncology agents. Vigeo is developing VT1021 as a therapeutic agent across a range of cancers, with a current focus on solid tumors. Vigeo Therapeutics is advancing VT1021 into a Phase II/III registrational study through the company’s collaboration with the Global Coalition for Adaptive Research (GCAR).

  • Varlilumab: Celldex Therapeutics

Varlilumab is a fully human monoclonal antibody that targets CD27, a critical molecule in the activation pathway of lymphocytes. CD27 can be effectively manipulated with activating antibodies to induce potent anti-tumor responses and may result in fewer toxicities due to its restricted expression and regulation.

Varlilumab is a potent anti-CD27 agonist that induces activation and proliferation of human T cells when combined with T cell receptor stimulation. Varlilumab has completed a Phase I dose-escalation study, demonstrating potent immunologic activity consistent with its mechanism of action and anti-tumor activity in patients with advanced, refractory disease. No maximum tolerated dose was reached and minimal toxicities were observed. Celldex initiated a broad development program for varlilumab to explore its role as an immune activator in combination with a number of complementary investigational and approved oncology drugs. Currently, the drug is in the Phase II stage of its development for the treatment of glioblastoma multiforme.

  • Debio 0123: Debiopharm

Debio 0123 is a Wee1 kinase inhibitor. The compound is being developed based on the deepened understanding of the DNA damage response (DDR) of cancer cells. Inhibition of WEE1 prevents cells to arrest or repair DNA damages and force them to prematurely continue through the cell cycle, therefore accumulating unrepaired DNA damages ultimately leading to cell death. The compound is being developed in light of the need to improve cancer patients’ treatment response and to overcome treatment resistance to current therapies. Pre-clinical models have shown anti-tumor activity both as a single agent and in combination with carboplatin. The advancement of Debio 0123 into clinical studies will assess the therapeutic results for cancer patients in various tumor types. Currently, the drug is in the Phase I/II stage of its development for the treatment of Glioblastoma.

  • PRT3645: Prelude Therapeutics

PRT3645 is Prelude’s next generation CDK4/6 inhibitor with high tissue distribution and brain penetration. In preclinical studies, PRT3645 treatment resulted in concentration-dependent inhibition of cell proliferation in both glioblastoma (GBM) cell lines and in ER+/HER2- and HER2+ breast cancer lines. In vivo, orally administered PRT3645 was well tolerated and highly efficacious in a dose-dependent manner in orthotopic human breast cancer brain metastasis and GBM models. Currently, the drug is in the Phase I stage of its development for the treatment of Glioblastoma.

 

Dive into our Glioblastoma Pipeline Report to uncover promising therapies and breakthroughs. Gain insights that could shape the future of oncology @ Glioblastoma Treatment Therapies

 

Glioblastoma Therapeutics Assessment

There are approx. 195+ key companies which are developing the therapies for Glioblastoma. The Glioblastoma companies which have their Glioblastoma drug candidates in the most advanced stage, i.e. phase III include, Denovo BioPharma.

 

DelveInsight’s Glioblastoma pipeline report covers around 210+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

 

Download the Glioblastoma Pipeline Report to discover partnership opportunities and collaborate in driving impactful solutions forward @ Glioblastoma Clinical Trials Assessment

 

Glioblastoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

  • Oral
  • Intravenous
  • Subcutaneous
  • Parenteral
  • Topical

 

Glioblastoma Products have been categorized under various Molecule types such as

  • Recombinant fusion proteins
  • Small molecule
  • Monoclonal antibody
  • Peptide
  • Polymer
  • Gene therapy 

 

Dive into our detailed Glioblastoma Pipeline Report to discover groundbreaking advancements shaping the future of cancer treatment @ Glioblastoma Products, Companies, and Unmet Needs

 

Scope of the Glioblastoma Pipeline Report

  • Coverage- Global
  • Glioblastoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Glioblastoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Glioblastoma Companies- Denovo BioPharma, Pfizer, Vigeo Therapeutics, Celldex Therapeutics, Debiopharm, Prelude Therapeutics, AiVita Biomedical, Ascletis Pharma, Kintara Therapeutics, Bayer AG, Kazia Therapeutics, GlaxoSmithKline, Candel Therapeutics, Symphogen A/S, Sanofi, Oblato, Jiangsu Hengrui Medicine, BPGbio, Inc., Alaunos Therapeutics, Eli Lilly and Company, Actuate Therapeutics, Oncotelic Therapeutics, The Menarini Group, SonALAsense, Novartis, Allarity Therapeutics, PharmAbcine, I-Mab Biopharma Co. Ltd., Aadi Bioscience, Inc., Matrix Biomed, Photonamic GmbH & Co. KG, Lixte, Black Diamond Therapeutics, Tmunity Therapeutics, SOM Biotech, Moleculin, Xynomic Pharmaceuticals, OncoSynergy, and others.
  • Glioblastoma Therapies- Axumin, Intravenous Solution, PolyMVA, MDNA55, Erlotinib HCl (OSI-774), BPM31510, Temozolomide (TMZ), and others.

 

Gain valuable insights into emerging therapies and innovations with our Glioblastoma Pipeline Report @ Glioblastoma Market Drivers and Barriers, Future Perspectives and Analyst Views

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Glioblastoma: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Glioblastoma– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Enzastaurin: Denovo BioPharma
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. Varlilumab: Celldex Therapeutics
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. PRT3645: Prelude Therapeutics
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. ELC-401: Elicera Therapeutics
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Glioblastoma Key Companies
  21. Glioblastoma Key Products
  22. Glioblastoma- Unmet Needs
  23. Glioblastoma- Market Drivers and Barriers
  24. Glioblastoma- Future Perspectives and Conclusion
  25. Glioblastoma Analyst Views
  26. Glioblastoma Key Companies
  27. Appendix

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Glioblastoma Pipeline Drugs 2024 | Denovo BioPharma, Pfizer, Vigeo Therapeutics, Celldex Therapeutics, Debiopharm, Prelude Therapeutics, AiVita Biomedical, Ascletis Pharma

Decision Intelligence Market Future Growth, Opportunities Business Scenario, Share, Global Size, Scope, Key Segments And Forecast To 2030

“IBM(US), Oracle (US), Google (US), Intel (US), Microsoft (US), TCS(INDIA), DOMO(US), Board International (Switzerland), Provenir (New Jersey), Pyramid Analytics (Netherlands), 4CAST(Israel), H20.ai(CA), Remi.AI (Australia), Quantellia (US), Peak.AI (UK), DIWO(US), Cerebra (US), Clarifai (US).”
Decision Intelligence Market by Offering (Platforms, Solutions (Integrated & Standalone), Services), Type (Decision Automation, Decision Augmentation, Decision Support System (DSS)), Business Function, Vertical and Region – Global Forecast to 2030.

The Decision intelligence market is expected to grow from USD 13.3  billion in 2024 to USD 50.1 billion in 2030, at a CAGR of 24.7%  during the forecast period. The global decision intelligence market is witnessing substantial growth driven by factors such as the exponential growth of digital data from diverse sources, advancements in AI and machine learning technologies, the need for real-time insights for agile decision-making, a focus on enhancing customer experiences, and industry-specific applications. Businesses across sectors leverage decision intelligence tools to extract actionable insights from vast datasets, automate decision-making processes, improve decision outcomes, and gain a competitive edge. This market trend underscores the growing recognition of data-driven decision-making as a strategic imperative for organizations worldwide.

Download PDF Brochure@ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=11498239  

By offering the services segment to account for higher CAGR during the forecast period.

In the decision intelligence market, the highest CAGR of services is fueled by complex decision-making processes, AI and machine learning advancements, real-time insights demand, big data analytics integration, business process optimization, cloud-based solutions adoption, data-driven culture, and diverse industry adoption. These trends reflect a global shift towards leveraging data for competitive advantage, driving a continuous need for sophisticated decision intelligence services across sectors. As businesses prioritize agility and informed decision-making, the decision intelligence market is expected to sustain significant growth, supported by evolving technologies and a growing emphasis on data-centric strategies.

By Type, Decision Automation is expected to hold the largest market size for the year 2024.

Decision automation contributes to cost savings and operational efficiencies by reducing manual intervention, minimizing errors, and optimizing resource allocation based on data-driven insights. This aligns with business objectives focused on improving productivity and profitability while maintaining accuracy and consistency in decision-making. Moreover, advancements in cloud computing facilitate the scalability, flexibility, and accessibility of decision automation solutions, making them more attractive to organizations of all sizes and industries. As businesses strive to stay competitive in a data-driven landscape, the growth of decision automation in the decision intelligence market is expected to continue as a strategic investment in enhancing agility, efficiency, and competitive advantage.

By Vertical, Retail & eCommerce is projected to grow at the highest CAGR during the forecast period.

The retail and e-commerce sector is experiencing a surge in the adoption of decision intelligence (DI) due to a confluence of factors. The exponential growth of e-commerce has resulted in vast repositories of customer data. While rich in potential insights, this data surge presents a challenge for traditional business intelligence (BI) tools. Here, DI leverages machine learning (ML) and advanced analytics to transform this data into actionable insights. Retailers can utilize DI for real-time personalization, optimizing product recommendations and marketing campaigns. Additionally, DI empowers data-driven inventory management, minimizing stockouts and maximizing efficiency. Furthermore, DI can bolster fraud prevention efforts and optimize supply chain logistics. In a competitive digital landscape, retailers increasingly recognize DI as a strategic imperative for enhancing customer experience, boosting operational efficiency, and gaining a competitive edge.

Asia Pacific is expected to grow at the highest CAGR during the forecast period.

The Asia-Pacific (APAC) region is experiencing rapid growth in the decision intelligence market, boasting the highest Compound Annual Growth Rate (CAGR). This surge is primarily attributed to rising demand for data-driven decision-making solutions, expanding digital transformation initiatives across industries, and a burgeoning startup ecosystem focusing on analytics and insights. Moreover, the region’s favorable regulatory environment, growing investments in big data analytics, and the integration of advanced technologies like the Internet of Things (IoT) further propel APAC’s dominance in decision intelligence market growth.

Request Sample Pages@ https://www.marketsandmarkets.com/requestsampleNew.asp?id=11498239  

Unique Features in the Decision Intelligence Market

The smooth fusion of artificial intelligence and human knowledge is a distinguishing feature of the decision intelligence business. DI systems use AI to analyze large volumes of data, spot trends, and offer useful insights, all with the goal of improving human decision-making. This combination preserves human critical judgment and contextual awareness while enabling companies to make better informed decisions.

Tools for decision intelligence have the special ability to provide scenario- and context-based analysis. With the use of these platforms, users can study the possible results of certain decisions before making them by simulating numerous scenarios.

Real-time data processing is a defining feature of many Decision Intelligence platforms. These tools can continuously ingest and analyze data as it becomes available, enabling real-time decision-making. Coupled with predictive analytics, DI platforms can forecast future trends and outcomes, helping organizations to anticipate changes and act proactively rather than reactively.

Automation is a significant trend in the Decision Intelligence market. Some DI platforms offer automated decision-making capabilities, where the system can make certain decisions autonomously based on predefined criteria and real-time data inputs. This feature is particularly useful in environments that require rapid, consistent decisions, such as in supply chain management, customer service, and financial trading.

Transparency in AI-driven decision-making is a unique feature increasingly emphasized in the Decision Intelligence market. Many DI platforms incorporate Explainable AI (XAI) techniques, which allow users to understand how and why a particular decision or recommendation was made by the AI.

Major Highlights of the Decision Intelligence Market

A wide range of industries, including finance, healthcare, retail, manufacturing, and logistics, are adopting decision intelligence technology at an accelerated rate. Businesses are using DI technologies to increase operational efficiency, strengthen decision-making, and obtain a competitive advantage.

The substantial developments in artificial intelligence and machine learning that support decision intelligence platforms are a major selling point of the market. With the help of these technologies, complex datasets can now yield deeper insights, greater pattern identification, and forecasts that are more accurate. As AI algorithms continue to advance, DI systems are able to provide increasingly complex analysis and decision assistance, which is spurring market innovation.

The expansion of predictive and prescriptive analytics is a major trend in the Decision Intelligence market. Predictive analytics enables organizations to forecast future trends and outcomes based on historical data, while prescriptive analytics provides recommendations on the best course of action. The ability to not only predict but also prescribe actions based on data is transforming how businesses approach strategic planning and operational decisions.

Real-time decision-making capabilities are becoming a central feature of the Decision Intelligence market. As businesses operate in increasingly fast-paced environments, the need for timely decisions is critical. DI platforms that offer real-time data processing and instant insights are gaining traction, particularly in sectors like finance, supply chain management, and customer service, where rapid responses can significantly impact performance and outcomes.

The growing emphasis on explainability and trust in AI-driven decisions is shaping the Decision Intelligence market. Organizations are increasingly concerned with understanding the rationale behind AI-generated recommendations to ensure they align with business goals and ethical standards. As a result, DI platforms are incorporating features that provide transparency and explainability, fostering greater trust in AI-assisted decision-making processes.

Inquire Before Buying@ https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=11498239  

Top Companies in the Decision Intelligence Market

The major decision intelligence solution and service providers include IBM(US), Oracle (US), Google (US), Intel (US), Microsoft (US), TCS(INDIA), DOMO(US), Board International (Switzerland), Provenir (New Jersey), Pyramid Analytics (Netherlands), 4CAST(Israel), H20.ai(CA), Remi.AI (Australia), Quantellia (US), Peak.AI (UK), DIWO(US), Cerebra (US), Clarifai (US), FLYR LABS(US), Metaphacts (Germany), Systems Technology Group (US),paretos(Germany), Course5i(US), Telius (US), Evolution Analytics (US), HyperFinity (UK), Aera Technology (US), Quantexa (UK), Urbint(US), PlanningForce(Belgium), EY(UK). These companies have used both organic and inorganic growth strategies such as product launches, acquisitions, and partnerships to strengthen their position in the decision intelligence market.

Oracle offers a diverse range of products, solutions, and services tailored to the needs of corporate IT environments, encompassing platforms, applications, and infrastructure. Its clientele spans businesses of varying sizes, government entities, educational institutions, and resellers. Oracle engages a global sales force and leverages the Oracle Partner Network to market its offerings worldwide. The company specializes in developing, manufacturing, and promoting hardware systems, databases, middleware, and application software. It also provides Software as a Service (SaaS) solutions integrating cutting-edge technologies such as IoT, AI, ML, and blockchain. Operating through three core business segments—cloud and license, hardware, and services—Oracle extends its reach to over 175 countries, serving a vast customer base exceeding 430,000 across industries such as banking, telecommunicatiasons, engineering, financial services, healthcare, insurance, public sector, retail, and utilities. Its global footprint spans the Americas, Europe, Asia Pacific, and the Middle East & Africa, catering to customers in over 145 countries.

In the decision intelligence market, Oracle leverages its robust data management capabilities and advanced analytics tools to provide businesses with valuable insights for informed decision-making. By integrating machine learning, artificial intelligence, and data visualization technologies into its platforms, Oracle enables organizations to extract actionable intelligence from complex data sets. This helps businesses to optimize processes, improve customer experiences, and gain competitive advantages in dynamic market environments. Oracle’s comprehensive suite of decision intelligence solutions equips enterprises with the tools to navigate complexities, mitigate risks, and drive sustainable growth in an increasingly data-driven world.

Google, a subsidiary of Alphabet Inc., is a multinational technology company renowned for its search engine, cloud computing services, software products, and hardware devices. In 1998, Google has evolved into one of the world’s most influential and innovative corporations, offering various digital solutions to individuals and businesses globally. Its core search engine, known for its accuracy and efficiency, processes billions of search queries daily, making it the primary gateway to information on the internet. Google’s product ecosystem includes popular services such as Gmail, Google Drive, Google Maps, YouTube, and the Android operating system, which dominate their respective markets.

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:630 Dundee Road Suite 430
City: Northbrook
State: IL 60062
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/decision-intelligence-market-11498239.html

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Decision Intelligence Market Future Growth, Opportunities Business Scenario, Share, Global Size, Scope, Key Segments And Forecast To 2030